XERS Form 4: Option Exercise at $6.66 and Weighted Sale at $7.92

Rhea-AI Filing Summary

Jeffrey W. Sherman, a director of Xeris Biopharma Holdings, Inc. (XERS), reported insider transactions on 08/28/2025. He exercised a stock option to acquire 47,040 shares at an exercise price of $6.66 and, on the same date, sold 42,232 shares at a weighted-average price of $7.9209. After these transactions he beneficially owned 219,188 shares directly and an additional 5,400 shares indirectly through the Jeffrey W Sherman Living Trust, for a disclosed total of 224,588 shares reported on this Form 4. The option exercised was originally granted in 2016 (assumed in an acquisition) and vests fully; the option grant underlying the exercised shares shows an expiration date of 10/01/2026.

Positive

• Exercised vested options to acquire 47,040 shares at an exercise price of $6.66
• Disclosed indirect trust holdings of 5,400 shares (Jeffrey W Sherman Living Trust)

Negative

• Sold 42,232 shares at a weighted-average price of $7.9209, reducing direct holdings
• Net change in direct reported shares shows a decrease from 261,420 to 219,188 after transactions

Insights

Financial Analyst

TL;DR: Director exercised options for 47,040 shares at $6.66 and sold 42,232 shares at ~$7.92 on 08/28/2025; net direct holdings remain substantial.

The reporting shows a routine exercise-and-partial-sale transaction: the director converted vested options into shares and disposed of a portion at a weighted-average price of $7.9209. The filings disclose remaining direct ownership of 219,188 shares and an indirect 5,400 shares in a trust. These are straightforward Section 16 transactions with no additional compensatory or novel financing terms reported.

Corporate Governance Expert

TL;DR: Transactions are standard for insiders exercising vested options and selling shares; disclosures appear complete and properly signed.

The Form 4 identifies the reporting person as a director and provides required details: transaction codes, amounts, prices (weighted average for sales), and a trust disclosure for indirect holdings. The form includes the reporting attorney-in-fact signature and an explanation of the option origin. No amendments or flags are present in the visible document.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SHERMAN JEFFREY W

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO IL 60607

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/28/2025		M		47,040	A	$6.66	261,420	D
Common Stock	08/28/2025		S		42,232	D	$7.9209(1)	219,188	D
Common Stock								5,400(2)	I	By: JEFFREY W SHERMAN LIVING TRUST U/A DTD 03/21/2001

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.66	08/28/2025		M			47,040	(3)	10/01/2026	Common Stock	47,040	$0	0	D

Explanation of Responses:

1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.920 to $7.935, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

2. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

3. On October 1, 2016, the reporting person was granted an option to purchase shares of Strongbridge Biopharma plc ("Strongbridge") which were assumed by Issuer in connection with the acquisition of Strongbridge. The options vested in full on October 5, 2021.

Remarks:

	/s/ Beth Hecht, Attorney-in-Fact	08/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions were reported for XERS on 08/28/2025?

Jeffrey W. Sherman exercised 47,040 option shares at $6.66 and sold 42,232 common shares at a weighted-average price of $7.9209 on 08/28/2025.

How many XERS shares does Jeffrey W. Sherman beneficially own after the Form 4?

The Form 4 reports 219,188 shares directly and 5,400 shares indirectly via the Jeffrey W Sherman Living Trust (total reported 224,588).

What was the exercise price and expiration for the option exercised by the XERS director?

The exercised stock option had an exercise price of $6.66 and the option shows an expiration date of 10/01/2026 in the filing.

What price range did the reported sales occur at for XERS shares?

The filing states the sale transactions occurred at prices ranging from $7.920 to $7.935, with a reported weighted-average sale price of $7.9209.

Who signed the Form 4 filing for the XERS reporting person?

The Form 4 is signed by /s/ Beth Hecht, Attorney-in-Fact dated 08/29/2025 on behalf of the reporting person.